ARTICLES BY KATE HAMMEKE

• How Do Outsourcers Feel About The CDMO Industry?

  10/2/2023

  Now is the time for company leaders at all stages to evaluate insurance costs, which can be among the top five most significant budget line items.

• Which CDMO Traits Predict Sponsor Loyalty When Outsourcing Small Molecule API?

  8/1/2023

  Using data from Industry Standard Research’s Small Molecule API CDMO Benchmarking report, ISR ran a regression analysis to identify which contract manufacturer characteristics are most-closely related to sponsor loyalty.

• COVID Continues To Impact Outsourced Manufacturing And Supply Chain Security

  4/3/2023

  ISR shares results from its annual benchmarking surveys on how the COVID-19 pandemic has impacted outsourced manufacturing over the past three years as well as how drug innovators plan to reduce risk and improve supply chain security going forward.

• CDMO Performance On Service Provider Selection Criteria

  3/1/2023

  ISR explains how LSL’s CDMO Leadership Awards and the corresponding market research data can be used by biopharma companies to make more informed CDMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.

• Clinical Manufacturing Outsourcing Practices Are in Flux

  2/1/2023

  As the clinical manufacturing space becomes more specialized with new providers entering the market to offer customized solutions for advanced therapies, we see outsourcers refining their service-provider-selection criteria and shifting some of their usage patterns.

• Where Bioprocessing Outsourcers Stand On Capacity Concerns

  10/11/2022

  Insights into bioprocessing outsourcers’ level of concern regarding current and upcoming available capacity, whether they are currently facing limits, and what they plan to do about a potential shortage.

• Where Bioprocessing Outsourcers Stand On Capacity Concerns

  10/3/2022

  Insights into bioprocessing outsourcers’ level of concern regarding current and upcoming available capacity, whether they are currently facing limits, and what they plan to do about a potential shortage.

• Outsourcers Who Most Heavily Rely On CDMOs Often Lack CDMO Selection Resources

  8/1/2022

  The 2022 iteration of ISR’s CDMO Outsourcing Models report relays similarities and differences in how outsourcing decisions are made at drug innovator companies of various sizes.

• Outsourcing Differences By Company Size — Biologic Drug Substance Manufacturing

  6/1/2022

  ISR split the data from its most recent Biologic API CDMO Benchmarking report by large and non-large respondents to highlight the differences in outsourcing preferences and practices.

• Outsourcers Are Feeling Uneasy About Continuity of Supply

  4/14/2022

  Find out how COVID-19 complications have picked up from the first year, with more outsourcers experiencing bigger obstacles when it comes to manufacturing, specifically with drug product.

• Outsourcers Are Feeling Uneasy About Continuity of Supply

  4/1/2022

  In its two most recent iterations, ISR’s annual CDMO Benchmarking research asked if and how the COVID-19 pandemic has impacted outsourced manufacturing. Interestingly, complications have picked up from the first year, with more outsourcers relaying bigger obstacles when it comes to manufacturing, specifically with drug product.

• Have CDMO Selection Criteria Changed Over The Past Five Years?

  3/16/2022

  New relationship dynamics between sponsors and CDMOs contribute to new trends appearing in the outsourced activities and services as well as the way CDMO selection decisions are made. ISR shares how CDMO selection criteria has changed over the past five years and links the attributes to the Life Science Leader’s CDMO Leadership Awards categories.

   
• Have CDMO Selection Criteria Changed Over the Past Five Years?

  3/1/2022

  Industry Standard Research shares how CDMO selection criteria have changed over the past five years and links the attributes to Life Science Leader’s CDMO Leadership Awards categories. This information be used by biopharma companies to make more informed CMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.

• What's Happening In Cell & Gene Therapy Development?

  2/8/2022

  This ISR report provides support and direction for innovative companies looking to outsource aspects of their cell and gene therapy manufacturing and development through shared research highlights.

• What's Happening In Cell & Gene Therapy Development?

  2/1/2022

  This ISR report is designed to help provide some support and direction for innovator companies looking to outsource aspects of their cell and/or gene therapy development and manufacturing and this article shares some highlights learned in the research.